Prescribing information

       

Welcome to the ILARIS: On-demand webinars page. Below you can access the latest educational webinars organised and funded by Novartis and hosted by experts in their field.

Contact your Novartis representative if you would like to express interest in registering for future events.

Contact us

 

FMF: Optimising patient care

Watch Prof. Jasmin Kümmerle-Deschner and Prof. Maria Cristina Maggio discuss key treatment goals in the management of patients with familial Mediterranean fever (FMF).  

Watch

Autoinflammatory diseases and the role of interleukin-1ß

Watch Prof. Paul Brogan, Prof. Helen Lachmann and Prof. Siniša Savić in this educational video about autoinflammatory disease (AID) such as periodic fever syndromes and Still’s disease.

Watch

 

 

consult-expert-eular-video-placeholder

AOSD: Improving patients’ treatment with targeted strategies

Watch Prof. Lorenzo Dagna and Prof. Jürgen Rech explore the role of targeted therapies in patients with adult-onset Still’s disease (AOSD).

Watch

Exploring the Still’s disease continuum and how to optimally manage patients

Watch Prof. Athimalaipet V Ramanan and Prof. Sinisa Savic discuss the differences between children and adults who present with Still’s disease and the protocols required for treatment.

Watch

 

Indications
Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:1

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • TRAPS
  • HIDS/MKD
  • FMF
    • ILARIS should be given in combination with colchicine, if appropriate.

Still's disease
ILARIS is indicated for the treatment of active Still's disease including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. ILARIS can be given as monotherapy or in combination with methotrexate.1

AID, autoinflammatory disorder; AOSD, adult-onset Still's disease; CAPS, cryopyrin-associated periodic syndrome; CINCA, chronic infantile neurological, cutaneous, articular syndrome; FCAS, severe forms of familial cold autoinflammatory syndrome; FCU, familial cold urticaria; FMF, familial Mediterranean fever; HCP, healthcare professional; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease; NSAID, non-steroidal anti-inflammatory drug; SJIA, systemic juvenile idiopathic arthritis; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

Reference

  1. ILARIS® (canakinumab) Summary of Product Characteristics.
Rate this content: 
Average: 4 (1 vote)
UK | May 2023 | 276818

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]